

AMENDMENTS TO THE SPECIFICATION

Please amend the third paragraph at page 11, lines 22-23 as follows:

The medicament of the present invention comprises a basic ~~metals~~ metal ion, in addition to the active ingredient (2R)-2-propyloctanoic acid or a salt thereof.

Please amend the first full paragraph at page 13, lines 17-26 as follows:

In addition to these, use can be also made of, for example, sodium aspartate, sodium glutamate, sodium acetyltryptophan, sodium caprylate, sodium gluconate, sodium salicylate, sodium diethylenetriamine pentaacetate, sodium thioglycolate, potassium thiocyanate, sodium thiosulfate, sodium deoxycholate, potassium pyrosulfite, sodium pyrosulfite, sodium methanesulfobenzoate, sodium benzoate, sodium ~~pyrrolinate~~ pyrophosphate, potassium aspartate, potassium glutamate, potassium acetyltryptophan, potassium caprylate, potassium gluconate, potassium salicylate, potassium diethylenetriamine pentaacetate, potassium thioglycolate, sodium thiocyanate, potassium thiosulfate, potassium deoxycholate, potassium methanesulfobenzoate, potassium benzoate, potassium ~~pyrrolinate~~ pyrophosphate and the like.

Please amend the paragraph bridging pages 20-21:

The medicament of the present invention may further comprise suitable additives which are generally used for injections. The additives include, for example, aqueous solutions of 70 v/v% N-hydroxyethyl lactamide, D-sorbitol, D-mannitol, DL-methionine, L-aspartic acid, L-alanine, L-arginine, L-glutamic acid, L-lysine, potassium L-glutamate, sodium L-glutamate, L-cystine, L-cystein, L-histidine, L-methionine, N,N-dimethylacetamide, ascorbic acid, sodium acetyltryptophan, aminoethyl sulfonic acid, aminoacetic acid, gum Arabic, powdered acacia, alpha-thioglycerin, albumin, inositol, ethanol, ethyl urea, ethylenediamine, sodium calcium edetate, sodium edetate, oleic acid, sodium caprylate, sodium carmellose, xylitol, citric acid,

sodium citrate, disodium citrate, glycerin, calcium gluconate, sodium gluconate, magnesium gluconate, creatinine, chlorobutanol, gentisic acid ethanolamide, succinic acid, sesame oil, sodium chondroitin sulfate, sodium salicylate, diethanolamine, diethylene triamine pentaacetate, sorbitan sesquioleate, gelatin, gelatin hydrolysate, sorbitan fatty acid ester, soybean oil, thioglycolic acid, sodium thioglycolate, potassium thiocyanate, sodium thiomalate, sodium thiosulfate, camellia oil, dextran 40, dextran 70, sodium desoxycholate, triethanolamine, tromethamol, sodium formaldehyde, sulfoxylate, nicotinic amide, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, hydroxypropyl cellulose, castor oil, potassium pyrosulfite, sodium pyrosulfite, phenol, butyl hydroxyanisole, glucose, propylene glycol, sodium heparinate, benzyl alcohol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, Polysorbate 80, Macrogol 400, Macrogol 4000, maltose, meglumine, sodium methane sulfobenzoate, monoethanolamine, aluminum monostearate, polyoxyethylene sorbitan (20 E.O.) monolaurate, peanut oil, phosphoric acid, dipotassium phosphate, potassium dihydrogen phosphate, sodium sulfite, sodium hydrogen sulfite, benzoic acid, sodium benzoate, benzyl benzoate, aluminum chloride, sodium chloride, benzalkonium chloride, benzethonium chloride, magnesium chloride, zinc chloride, zinc chloride solution, tin(I) chloride, iron(II) chloride, hydrochloric acid, arginine chloride, cystein chloride, lysine chloride, fructose, dried aluminum gel, dried sodium sulfite, dilute hydrochloric acid, highly purified egg yolk lecithin, calcium oxide, zinc oxide, tartaric acid, calcium bromide, sodium bromide, acetic acid, ammonium acetate, sodium acetate, zinc acetate, aluminum hydroxide, purified gelatin, purified soybean lecithin, purified soybean oil, purified sucrose, purified egg yolk lecithin, sodium hydrogen

carbonate, water for injection, calcium sugar acid, lactic acid, ethyl lactate, a sodium lactate solution, lactose, urea, concentrated glycerin, glacial acetic acid, anhydrous ethanol, anhydrous citric acid, anhydrous sodium ~~pyrrolate~~ pyrophosphate, anhydrous maleic acid, anhydrous tin(II) chloride, anhydrous sodium acetate, sulfuric acid, potassium aluminum sulfate, potassium sulfate, magnesium sulfate and the like. These additives are generally mixed in the proportions used in conventional injections.

Please amend the second paragraph at page 23, lines 12-21:

The fat staining method includes, for example, a method of mixing a solution of a fat-soluble dye (for example, Sudan III, piacyanol chloride, Rhodamine 6G, *etc.*) with the solution under test, followed by centrifugation after a certain period of time, and measuring the absorbance of the supernatant which is inherent to the fat-soluble dye used. If the absorbance of the supernatant can be measured according to this test method, it implies that the fat-soluble dye is present within micelles, that is, micelles have been formed, and thus it is possible to determine that a micelle water dispersion liquid has been formed. It is also possible to define the critical concentration ~~[[or]]~~ of micelle formation, that is, a critical micelle concentration (CMC), by means of such a test.

Please amend the paragraph bridging pages 32-33:

Neurodegenerative diseases include, for example, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, olivopontocerebellar atrophy, cerebral stroke (for example, cerebral infarction, cerebral hemorrhage, *etc.*), or neurofunctional disorders after ~~neurospinal~~ cerebrospinal trauma (for example, demyelinating diseases (multiple sclerosis, *etc.*), brain cancer (astrocytoma, *etc.*), cerebrospinal diseases associated with infection (meningitis, pyocephalus, Creutzfeldt-Jakob disease, AIDS (HIV)

dementia, *etc.*)) and the like. Furthermore, the present medicament is useful as a nerve regeneration promoter, an S100 β increase inhibitor, or a nerve disorder improver. The medicament of the present invention is administered into the living body under the purpose of treatment and/or prevention of the above-described diseases, after being converted to a form appropriate for administration to a patient by using a dissolving liquid and/or a diluting liquid.